Anaxsys secures £1m funding for respiratory sensor technology
15 Oct 2010
Anaxsys Ltd has secured £1 million additional investment to
accelerate the commercialisation of novel respiratory devices based on
its patented sensor technology.
Deryk Williams, CEO of Anaxsys said, “This additional investment
will allow Anaxsys to accelerate the commercialization of respiR8,
our first product to market, and further the development of a range
of innovative respiratory devices based on our core sensor
technology.
"Anaxsys’ respiratory devices are developed with clinicians and
healthcare professionals in mind from the onset and have the
potential to revolutionise clinical practice. Our patented sensor
technology enables innovative respiratory devices that provide
accurate, reliable, simple to use and cost effective means to
significantly improve patient outcomes.”
Jason Gould, Fund Principal of South East Growth Fund said, “The
achievement of the CE Mark for respiR8 continuous respiratory rate
counter is a very significant milestone for the Company. It will
allow Anaxsys to implement their plans for full commercialisation of
respiR8 to the UK and European healthcare markets.
"Having consulted and collaborated with clinicians and other
healthcare professionals, Anaxsys identified that there is a great
unmet clinical need for respiratory rate monitoring, particularly in
perioperative environments, which respiR8 is ideally suited in
addressing. And clinical trials and studies of the device have
confirmed its effectiveness and commercial potential with healthcare
professionals.”
The investors who participated in the funding include South East
Growth Fund, Early Advantage Partnership and a number of business
angels. Anaxsys has received £5.7m of funding to date, which
includes £700,000 in grant finance.